{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:19:21Z","timestamp":1793031561954,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1158748"],"award-info":[{"award-number":["APP1158748"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1132975"],"award-info":[{"award-number":["APP1132975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Department of Education and Training | Australian Research Council","doi-asserted-by":"publisher","award":["FT230100468"],"award-info":[{"award-number":["FT230100468"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cyclic peptides are often used as scaffolds for the multivalent presentation of drug molecules due to their structural stability and constrained conformation. We identified a cyclic deca-peptide incorporating lipoamino acids for delivering T helper and B cell epitopes against group A <jats:italic>Streptococcus<\/jats:italic> (GAS), eliciting robust humoral immune responses. In this study, we assessed the function-immunogenicity relationship of the multi-component vaccine candidate (referred to as VC-13) to elucidate a mechanism of action. We identified a potential universal delivery platform, not only capable of adjuvanting different peptide epitopes (e.g., NS1 and 88\/30 from group A <jats:italic>Streptococcus<\/jats:italic>, gonadotropin hormone releasing hormone [GnRH]), but also protein antigens (e.g., bovine serum albumin [BSA], receptor binding domain (RBD) of the SARS-CoV-2 protein responsible for COVID-19 infection [SARS-CoV-2 RBD]) and small molecular haptens (e.g., cocaine). All vaccine candidates self-assembled into sub-500 nm nanoparticles and induced high antigen-specific systemic IgG titers and opsonic potential compared to the antigen co-administered with a commercial adjuvant, complete Freund\u2019s adjuvant. Notably, presence of the cyclic decapeptide in this vaccine increased accumulation in the draining inguinal lymph nodes, facilitating cellular uptake of peptide antigens. Furthermore, the lipoamino acid promoted dendritic cell activation, acting as both toll-like receptors 2 and 4 -targeting moiety. Our study revealed the importance of the cyclic decapeptide and lipoamino acid presence in antigen presentation and immune response activation, leading onto the development of a fully synthetic, self-assembled, and promising platform for the delivery of subunit vaccines and anti-drug vaccines.<\/jats:p>","DOI":"10.1038\/s41541-024-01050-4","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T02:57:56Z","timestamp":1736909876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A synthetic cyclic peptide for promoting antigen presentation and immune activation"],"prefix":"10.1038","volume":"10","author":[{"given":"Jiahui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8116-5194","authenticated-orcid":false,"given":"Harrison Y. R.","family":"Madge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-3688","authenticated-orcid":false,"given":"Wenbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashamsa","family":"Koirala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazmina L.","family":"Gonzalez Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahra","family":"Bashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed O.","family":"Shalash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-1880","authenticated-orcid":false,"given":"Waleed M.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab G.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-6940","authenticated-orcid":false,"given":"James W.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-7502","authenticated-orcid":false,"given":"Rachel J.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"1050_CR1","doi-asserted-by":"crossref","unstructured":"Louten, J. in Essential Human Virology (ed Jennifer Louten) 93\u2013109 (Academic Press, 2016).","DOI":"10.1016\/B978-0-12-800947-5.00006-5"},{"key":"1050_CR2","doi-asserted-by":"crossref","unstructured":"Sanina, N. Vaccine adjuvants derived from marine organisms. Biomolecules. 9 (2019).","DOI":"10.3390\/biom9080340"},{"key":"1050_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41570-020-00244-3","volume":"5","author":"C Pifferi","year":"2021","unstructured":"Pifferi, C., Fuentes, R. & Fern\u00e1ndez-Tejada, A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat. Rev. Chem. 5, 197\u2013216 (2021).","journal-title":"Nat. Rev. Chem."},{"key":"1050_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MOP.0000000000000868","volume":"32","author":"E Nanishi","year":"2020","unstructured":"Nanishi, E., Dowling, D. J. & Levy, O. Toward precision adjuvants: optimizing science and safety. Curr. Opin. Pediatr. 32, 125\u2013138 (2020).","journal-title":"Curr. Opin. Pediatr."},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/vaccines10071120","volume":"10","author":"J Fan","year":"2022","unstructured":"Fan, J. et al. Advances in infectious disease vaccine adjuvants. Vaccines 10, 1120 (2022).","journal-title":"Vaccines"},{"key":"1050_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3389\/fimmu.2017.00943","volume":"8","author":"W Burny","year":"2017","unstructured":"Burny, W. et al. Different adjuvants induce common innate pathways that are associated with enhanced adaptive responses against a model antigen in humans. Front. Immunol. 8, 943 (2017).","journal-title":"Front. Immunol."},{"key":"1050_CR7","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1128\/IAI.72.11.6519-6527.2004","volume":"72","author":"EH Nardin","year":"2004","unstructured":"Nardin, E. H. et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72, 6519\u20136527 (2004).","journal-title":"Infect. Immun."},{"key":"1050_CR8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1089\/aid.1995.11.1479","volume":"11","author":"D Salmon-C\u00e9ron","year":"1995","unstructured":"Salmon-C\u00e9ron, D. et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. Aids. Res. Hum. Retroviruses. 11, 1479\u20131486 (1995).","journal-title":"Aids. Res. Hum. Retroviruses."},{"key":"1050_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.121614","volume":"617","author":"W Huang","year":"2022","unstructured":"Huang, W. et al. Structure-activity relationship of lipid, cyclic peptide and antigen rearrangement of physically mixed vaccines. Int. J. Pharm. 617, 121614 (2022).","journal-title":"Int. J. Pharm."},{"key":"1050_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1039\/D1BM01333E","volume":"10","author":"HYR Madge","year":"2022","unstructured":"Madge, H. Y. R. et al. Physical mixture of a cyclic lipopeptide vaccine induced high titres of opsonic IgG antibodies against group A streptococcus. Biomater. Sci. 10, 281\u2013293 (2022).","journal-title":"Biomater. Sci."},{"key":"1050_CR11","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1021\/acs.jmedchem.0c00203","volume":"63","author":"HYR Madge","year":"2020","unstructured":"Madge, H. Y. R. et al. Structure\u2013activity analysis of cyclic multicomponent lipopeptide self-adjuvanting vaccine candidates presenting group A streptococcus antigens. J. Med. Chem. 63, 5387\u20135397 (2020).","journal-title":"J. Med. Chem."},{"key":"1050_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4062\/biomolther.2012.20.1.019","volume":"20","author":"SH Joo","year":"2012","unstructured":"Joo, S. H. Cyclic peptides as therapeutic agents and biochemical tools. Biomol. Ther. (Seoul.) 20, 19\u201326 (2012).","journal-title":"Biomol. Ther. (Seoul.)"},{"key":"1050_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102740","volume":"20","author":"LM Dooley","year":"2021","unstructured":"Dooley, L. M., Ahmad, T. B., Pandey, M., Good, M. F. & Kotiw, M. Rheumatic heart disease: a review of the current status of global research activity. Autoimmun. Rev. 20, 102740 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1050_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202115342","volume":"61","author":"A Mahmoud","year":"2022","unstructured":"Mahmoud, A., Toth, I. & Stephenson, R. Developing an effective glycan-based vaccine for streptococcus pyogenes. Angew. Chem. Int. Ed. 61, e202115342 (2022).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1050_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5694\/mja2.51126","volume":"215","author":"JW Cannon","year":"2021","unstructured":"Cannon, J. W. & Bowen, A. C. An update on the burden of group A streptococcal diseases in Australia and vaccine development. Med. J. Aust. 215, 27\u201328 (2021).","journal-title":"Med. J. Aust."},{"key":"1050_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","volume":"399","author":"L Bravo","year":"2022","unstructured":"Bravo, L. et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 399, 461\u2013472 (2022).","journal-title":"Lancet"},{"key":"1050_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","volume":"22","author":"S Sridhar","year":"2022","unstructured":"Sridhar, S. et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect. Dis. 22, 636\u2013648 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1050_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1586\/erv.10.102","volume":"9","author":"BM Kinsey","year":"2010","unstructured":"Kinsey, B. M., Kosten, T. R. & Orson, F. M. Anti-cocaine vaccine development. Expert Rev. Vaccines. 9, 1109\u20131114 (2010).","journal-title":"Expert Rev. Vaccines."},{"key":"1050_CR19","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.4049\/jimmunol.1401031","volume":"193","author":"SS Weber","year":"2014","unstructured":"Weber, S. S., Ducry, J. & Oxenius, A. Dissecting the contribution of IgG subclasses in restricting airway infection with legionella pneumophila. J. Immun. 193, 4053\u20134059 (2014).","journal-title":"J. Immun."},{"key":"1050_CR20","doi-asserted-by":"publisher","unstructured":"Dai, C. et al. Opsonic activity of conservative versus variable regions of the group A streptococcus M protein. Vaccines. 8 https:\/\/doi.org\/10.3390\/vaccines8020210 (2020).","DOI":"10.3390\/vaccines8020210"},{"key":"1050_CR21","doi-asserted-by":"crossref","unstructured":"Dai, C., Stephenson, R. J., Skwarczynski, M. & Toth, I. in Peptide Synthesis: Methods and Protocols (eds Waleed M. H, M Skwarczynski, & I Toth) 13-27 (Springer US, 2020).","DOI":"10.1007\/978-1-0716-0227-0_2"},{"key":"1050_CR22","doi-asserted-by":"publisher","first-page":"12407","DOI":"10.1021\/acs.jmedchem.3c00889","volume":"66","author":"HYR Madge","year":"2023","unstructured":"Madge, H. Y. R. et al. Synthetic anti-cocaine nanoaccine successfully prevents cocaine-induced hyperlocomotion. J. Med. Chem. 66, 12407\u201312419 (2023).","journal-title":"J. Med. Chem."},{"key":"1050_CR23","doi-asserted-by":"publisher","first-page":"40392","DOI":"10.1021\/acsami.1c11875","volume":"13","author":"K Tamarov","year":"2021","unstructured":"Tamarov, K. et al. Comparison between fluorescence imaging and elemental analysis to determine biodistribution of inorganic nanoparticles with strong light absorption. ACS Appl. Mater. Interfaces 13, 40392\u201340400 (2021).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1050_CR24","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3390\/cancers13092245","volume":"13","author":"H Takakura","year":"2021","unstructured":"Takakura, H., Sato, H., Nakajima, K., Suzuki, M. & Ogawa, M. In vitro and in vivo cell uptake of a cell-penetrating peptide conjugated with fluorescent dyes having different chemical properties. Cancers 13, 2245 (2021).","journal-title":"Cancers"},{"key":"1050_CR25","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"N-N Zhang","year":"2020","unstructured":"Zhang, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271\u20131283.e1216 (2020).","journal-title":"Cell"},{"key":"1050_CR26","doi-asserted-by":"publisher","unstructured":"Lu, L. et al. Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines in vitro. Front. Immunol. 15, https:\/\/doi.org\/10.3389\/fimmu.2024.1298721 (2024).","DOI":"10.3389\/fimmu.2024.1298721"},{"key":"1050_CR27","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1111\/j.1582-4934.2010.01127.x","volume":"14","author":"L Yu","year":"2010","unstructured":"Yu, L., Wang, L. & Chen, S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 14, 2592\u20132603 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"1050_CR28","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1172\/JCI23755","volume":"115","author":"L Schaefer","year":"2005","unstructured":"Schaefer, L. et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 42 macrophages. J. Clin. Invest. 115, 2223\u20132233 (2005).","journal-title":"J. Clin. Invest."},{"key":"1050_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcis.2012.11.061","volume":"395","author":"S Yan","year":"2013","unstructured":"Yan, S., Gu, W. & Xu, Z. P. Re-considering how particle size and other properties of antigen-adjuvant complexes impact on the immune responses. J. Colloid Interface Sci. 395, 1\u201310 (2013).","journal-title":"J. Colloid Interface Sci."},{"key":"1050_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/74719","volume":"6","author":"ER Brandt","year":"2000","unstructured":"Brandt, E. R. et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat. Med. 6, 455\u2013459 (2000).","journal-title":"Nat. Med."},{"key":"1050_CR31","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1086\/374800","volume":"187","author":"MR Batzloff","year":"2003","unstructured":"Batzloff, M. R. et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8- and diphtheria toxoid-specific antibodies to protection. J. Infect. Dis. 187, 1598\u20131608 (2003).","journal-title":"J. Infect. Dis."},{"key":"1050_CR32","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.eurpolymj.2017.02.014","volume":"93","author":"G Zhao","year":"2017","unstructured":"Zhao, G., Chandrudu, S., Skwarczynski, M. & Toth, I. The application of self-assembled nanostructures in peptide-based subunit vaccine development. Eur. Polym. J. 93, 670\u2013681 (2017).","journal-title":"Eur. Polym. J."},{"key":"1050_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4049\/jimmunol.145.1.215","volume":"145","author":"RB Forsyth","year":"1990","unstructured":"Forsyth, R. B. & Hoffmann, G. W. A study of auto-anti-idiotypes to BSA. J. Immunol. 145, 215\u2013223 (1990).","journal-title":"J. Immunol."},{"key":"1050_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.04.003","volume":"140","author":"TR Kosten","year":"2014","unstructured":"Kosten, T. R. et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depen. 140, 42\u201347 (2014).","journal-title":"Drug Alcohol Depen."},{"key":"1050_CR35","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","volume":"20","author":"TR Kosten","year":"2002","unstructured":"Kosten, T. R. et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20, 1196\u20131204 (2002).","journal-title":"Vaccine"},{"key":"1050_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","volume":"66","author":"BA Martell","year":"2009","unstructured":"Martell, B. A. et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiat 66, 1116\u20131123 (2009).","journal-title":"Arch. Gen. Psychiat"},{"key":"1050_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biopsych.2005.04.032","volume":"58","author":"BA Martell","year":"2005","unstructured":"Martell, B. A., Mitchell, E., Poling, J., Gonsai, K. & Kosten, T. R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiat 58, 158\u2013164 (2005).","journal-title":"Biol. Psychiat"},{"key":"1050_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.biopsych.2009.08.031","volume":"67","author":"M Haney","year":"2010","unstructured":"Haney, M., Gunderson, E. W., Jiang, H., Collins, E. D. & Foltin, R. W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiat 67, 59\u201365 (2010).","journal-title":"Biol. Psychiat"},{"key":"1050_CR39","doi-asserted-by":"publisher","unstructured":"Faruck, M. O. et al. Polyacrylate-GnRH peptide conjugate as an oral contraceptive vaccine candidate. Pharmaceutics. 13, https:\/\/doi.org\/10.3390\/pharmaceutics13071081 (2021).","DOI":"10.3390\/pharmaceutics13071081"},{"key":"1050_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/M566","volume":"2008","author":"BP Ross","year":"2008","unstructured":"Ross, B. P., Falconer, R. A. & Thot, I. N-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (N-Dde) lipoamino acids. Molbank 2008, M566 (2008).","journal-title":"Molbank"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01050-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01050-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01050-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T02:58:01Z","timestamp":1736909881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01050-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01050-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}